PDCD1 and neoplasm: We assayed primary tumor growth using a VCaP castration resistant model in huNOG mice to evaluate the model in a more enzalutamide sensitive setting, determine if we could enhance the effects of immune activation by treatment with a checkpoint inhibitor in the form of the anti-PD1 pembrolizumab (pembro).